Sorafenib: delivering a targeted drug to the right targets

References

• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol.23, 6771–6790 (2005).
   PubMed Web of Science ®Google Scholar
• Hood JD, Bednarski M, Frausto R et al. Tumor regression by targeted gene delivery to the neovasculature. Science296, 2404–2407 (2002).
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Yao KS, Gallagher M et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol.17, 2227–2236 (1999).
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, Stevenson JP, Gallagher M et al. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res.5, 3977–3982 (1999).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res.62, 6997–7000 (2002).
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res.63, 5198–5202 (2003).
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Ogilvie L, Hedley D et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res.64, 2338–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Sumimoto H, Miyagishi M, Miyoshi H et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene23, 6031–6039 (2004).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst.98, 326–334 (2006).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol.23, 965–972 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol.19, 843–850 (2001).
   PubMed Web of Science ®Google Scholar
• Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res.8, 2798–2805 (2002).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med.344, 1031–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24, 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Sosman JA, Flaherty KT, Atkins MB et al. A Phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients. J. Clin. Oncol.24(S18) 3031, 6–20 (2006).
   PubMedGoogle Scholar
• Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43–9006. J. Clin. Oncol.24, 1363–1369 (2006).
   PubMed Web of Science ®Google Scholar
• Ziche M, Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest.99, 2625–2634 (1997).
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y, Schmidt L et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet.7, 85–90 (1994).
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Zhou S, Merrill MJ et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA93, 10589–10594 (1996).
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel–Lindau protein. Proc. Natl Acad. Sci. USA93, 10595–10599 (1996).
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, Rosen M, Gallagher M, Schwartz B, Flaherty KT. Pharmacodynamic study of BAY 43–9006 in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.23(S16), 3005 (2005).
   Google Scholar
• Escudier B, Eisen T, Stadler WM et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Yang L, Carbone DP. Tumor–host immune interactions and dendritic cell dysfunction. Adv.Cancer Res.92, 13–27 (2004).
   PubMed Web of Science ®Google Scholar
• Gollob J, Richmond T, Jones J et al. Phase II trial of sorafenib plus interferon-α 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J. Clin. Oncol.24(S18), 4538 (2006).
   Google Scholar
• Ryan CW, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon-a2β (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J. Clin. Oncol.24(S18), 4525 (2006).
   Google Scholar
• Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43–9006. J. Clin. Oncol.24, 1363–1369 (2006).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol.24(S18), LBA4 (2006).
   Google Scholar
• Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res.66, 5549–5554 (2006).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.24(26), 4293–42300 (2006).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Brose M, Schuchter LM et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J. Clin. Oncol.22(S14), 7507 (2004).
   Google Scholar
• Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am. J. Clin. Oncol.25, 283–286 (2002).
   PubMed Web of Science ®Google Scholar
• Zimpfer-Rechner C, Hofmann U, Figl R et al. Randomized Phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res.13, 531–536 (2003).
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Schuchter LM, Kramer A et al. Preliminary results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J. Clin. Oncol.24(S18), 8009 (2006).
   Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18, 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Redlinger M, Schuchter LM, Lathia CD, Weber BL, O’Dwyer PJ. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma. J. Clin. Oncol.23(S16), 3037 (2005).
   Google Scholar